Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.87
INCY's Cash to Debt is ranked higher than
54% of the 1443 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. INCY: 0.87 )
INCY' s 10-Year Cash to Debt Range
Min: 0.35   Max: No Debt
Current: 0.87

Equity to Asset -0.10
INCY's Equity to Asset is ranked higher than
50% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INCY: -0.10 )
INCY' s 10-Year Equity to Asset Range
Min: -0.95   Max: 0.81
Current: -0.1

-0.95
0.81
F-Score: 4
Z-Score: 10.22
M-Score: -2.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -0.94
INCY's Operating margin (%) is ranked higher than
83% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -95.34 vs. INCY: -0.94 )
INCY' s 10-Year Operating margin (%) Range
Min: -4064.53   Max: 9.05
Current: -0.94

-4064.53
9.05
Net-margin (%) -9.48
INCY's Net-margin (%) is ranked higher than
80% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -77.05 vs. INCY: -9.48 )
INCY' s 10-Year Net-margin (%) Range
Min: -4565.45   Max: 7.67
Current: -9.48

-4565.45
7.67
ROA (%) -6.75
INCY's ROA (%) is ranked higher than
81% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. INCY: -6.75 )
INCY' s 10-Year ROA (%) Range
Min: -70.43   Max: 5.19
Current: -6.75

-70.43
5.19
ROC (Joel Greenblatt) (%) -8.46
INCY's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 1411 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. INCY: -8.46 )
INCY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4727.38   Max: 47.33
Current: -8.46

-4727.38
47.33
Revenue Growth (3Y)(%) 59.60
INCY's Revenue Growth (3Y)(%) is ranked higher than
97% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. INCY: 59.60 )
INCY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61.4   Max: 194.1
Current: 59.6

-61.4
194.1
EPS Growth (3Y)(%) -42.00
INCY's EPS Growth (3Y)(%) is ranked higher than
56% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. INCY: -42.00 )
INCY' s 10-Year EPS Growth (3Y)(%) Range
Min: -45.1   Max: 64.9
Current: -42

-45.1
64.9
» INCY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

INCY Guru Trades in Q1 2014

George Soros 23,200 sh (New)
Vanguard Health Care Fund 4,901,968 sh (+9.97%)
Manning & Napier Advisors, Inc Sold Out
Paul Tudor Jones Sold Out
Mariko Gordon 112,623 sh (-12.67%)
Steven Cohen 42,149 sh (-60.73%)
» More
Q2 2014

INCY Guru Trades in Q2 2014

Ken Fisher 12,225 sh (New)
Louis Moore Bacon 100,000 sh (New)
Vanguard Health Care Fund 9,591,143 sh (+95.66%)
George Soros Sold Out
Mariko Gordon 23,728 sh (-78.93%)
» More
Q3 2014

INCY Guru Trades in Q3 2014

Jim Simons 97,916 sh (New)
Mariko Gordon 25,283 sh (+6.55%)
Vanguard Health Care Fund 10,174,343 sh (+6.08%)
Mariko Gordon 16,500 sh (unchged)
Louis Moore Bacon Sold Out
Ken Fisher 7,545 sh (-38.28%)
» More
Q4 2014

INCY Guru Trades in Q4 2014

Jim Simons 244,800 sh (+150.01%)
Ken Fisher 14,870 sh (+97.08%)
Vanguard Health Care Fund 10,174,343 sh (unchged)
Mariko Gordon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Incyte Corp

Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Aramark, Incyte Corp Ltd. and Facebook Inc. Read more...
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN
According to GuruFocus Insider Data, the largest insider sells during the past week were: Aramark, Incyte Corp Ltd, Emeritus Corp, and Huntsman Corp. Read more...

Ratios

vs
industry
vs
history
Forward P/E 84.03
INCY's Forward P/E is ranked higher than
90% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: 84.03 )
N/A
P/S 35.24
INCY's P/S is ranked higher than
61% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 37.64 vs. INCY: 35.24 )
INCY' s 10-Year P/S Range
Min: 7.19   Max: 209.75
Current: 35.24

7.19
209.75
POCF 811.62
INCY's POCF is ranked higher than
88% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: 811.62 )
INCY' s 10-Year POCF Range
Min: 7.19   Max: 811.62
Current: 811.62

7.19
811.62
Current Ratio 3.16
INCY's Current Ratio is ranked higher than
67% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.39 vs. INCY: 3.16 )
INCY' s 10-Year Current Ratio Range
Min: 2.05   Max: 15.29
Current: 3.16

2.05
15.29
Quick Ratio 3.15
INCY's Quick Ratio is ranked higher than
68% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. INCY: 3.15 )
INCY' s 10-Year Quick Ratio Range
Min: 2.05   Max: 15.29
Current: 3.15

2.05
15.29
Days Inventory 43.30
INCY's Days Inventory is ranked higher than
94% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: 43.30 )
INCY' s 10-Year Days Inventory Range
Min: 46.41   Max: 323.15
Current: 43.3

46.41
323.15
Days Sales Outstanding 41.34
INCY's Days Sales Outstanding is ranked higher than
89% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. INCY: 41.34 )
INCY' s 10-Year Days Sales Outstanding Range
Min: 12.25   Max: 6447.52
Current: 41.34

12.25
6447.52

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.60
INCY's Price/Median PS Value is ranked higher than
79% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. INCY: 1.60 )
INCY' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 4.4
Current: 1.6

0.14
4.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ICY.Germany,
Incyte Corp was incorporated in Delaware in 1991. It is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology. Its pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company faces competition from organizations, particularly fully integrated pharmaceutical companies that are pursuing pharmaceuticals that are competitive with JAKAFI and its drug candidates. Its trademaks include Incyte and JAKAFI. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its drug candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries.
» More Articles for INCY

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 
Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Feb 24 2014 
Weekly CEO Sells Highlight: ExOne Co, Atmel Corporation, Best Buy and Incyte Corp Ltd. Sep 22 2013 
Weekly CFO Sells Highlight: INTU, INCY, RLD, MIDD, XONE Sep 15 2013 
Weekly CEO Sells Highlight: DIS, LMT, INCY, ADBE May 14 2012 
Weekly Top Insider Buys: VTR, INCY, FULT, HMA, CMC Jan 23 2012 
04 stocks with insider buying of more than $1.5 million since beginning of 2012 Jan 22 2012 
Weekly CFO Sales Highlight: EPIQ, INCY, AVB, JOSB, PCS, FLO Jun 12 2011 

More From Other Websites
Incyte to Present at Upcoming Investor Conferences Apr 23 2015
Incyte to Present at Upcoming Investor Conferences Apr 23 2015
Will Agenus (AGEN) Disappoint in Q1 Earning Season? - Analyst Blog Apr 22 2015
Biotech Investors: May 29th Could Be A Big Day Apr 21 2015
Should Gilead Sciences Buy Vertex? Bernstein Says Yes, Maxim Says No Apr 21 2015
New data boosts biotechs Apr 20 2015
Incyte’s Emerging Development Pipeline Described in Eleven Abstracts at 2015 AACR Annual Meeting Apr 17 2015
INCYTE CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 17 2015
Incyte’s Emerging Development Pipeline Described in Eleven Abstracts at 2015 AACR Annual Meeting Apr 17 2015
AbbVie: Strong Data, Once Daily Dose 'Necessary to Ensure Strong Commercial Success' Apr 15 2015
Incyte to Establish European Headquarters in Geneva, Switzerland Apr 14 2015
Incyte to Report First Quarter Financial Results on April 30 Apr 14 2015
Incyte to Report First Quarter Financial Results on April 30 Apr 14 2015
Incyte to Establish European Headquarters in Geneva, Switzerland Apr 14 2015
INCYTE CORP Files SEC form 8-K, Change in Directors or Principal Officers Apr 13 2015
Novartis' Jakavi Gets EC Approval for Polycythemia Vera - Analyst Blog Mar 18 2015
Jakavi® (ruxolitinib) Receives European Commission Approval as First Targeted Therapy for Patients... Mar 17 2015
Jakavi® (ruxolitinib) Receives European Commission Approval as First Targeted Therapy for Patients... Mar 17 2015
Baker Bros. Advisors Hits the Jackpot with Pharmacyclics Inc (PCYC) Sale; Incyte Corporation (INCY)... Mar 05 2015
Biotech Incyte has both sales and pipeline Mar 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK